Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Reproductive Health Drugs Cmte. returns

Executive Summary

FDA's Reproductive Health Drugs Adivisory Committee will break a three year hiatus with a Sept. 29 meeting on clinical trial design issues and outcome measures for drugs seeking indications for induction of ovulation and pregnancy in anovulatory infertile women and development of multiple follicles in pregnancy in ovulatory women participating in assisted reproductive technology programs. It is the first meeting of the committee since Sept. 12, 2000, and since its reconstitution with new members in December 2002 (1"The Pink Sheet" Jan. 6, 2003, p. 15)...

You may also be interested in...

FDA Reproductive Health Cmte. Line-Up Set; First Priority Will Be WHI Results

The new roster of FDA's Reproductive Health Drugs Advisory Committee includes two members who have conducted research or educational activities on hormone replacement therapy sponsored by Wyeth

US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline

With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?

ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN

Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts